The global Pediatrics Medicine market size will be USD 131542.2 million in 2024.

According to Cognitive Market Research, the global Pediatrics Medicine market size will be USD 131542.2 million in 2024. It will expand at a compound annual growth rate (CAGR) of 13.20% from 2024 to 2031.North America held the major market share for more than 40% of the global revenue with a market size of USD 52616.88 million in 2024 and will grow at a compound annual growth rate (CAGR) of 11.4% from 2024 to 2031.Europe accounted for a market share of over 30% of the global revenue with a market size of USD 39462.66 million.Asia Pacific held a market share of around 23% of the global revenue with a market size of USD 30254.71 million in 2024 and will grow at a compound annual growth rate (CAGR) of 15.2% from 2024 to 2031.Latin America had a market share of more than 5% of the global revenue with a market size of USD 6577.11 million in 2024 and will grow at a compound annual growth rate (CAGR) of 12.6% from 2024 to 2031.Middle East and Africa had a market share of around 2% of the global revenue and was estimated at a market size of USD 2630.84 million in 2024 and will grow at a compound annual growth rate (CAGR) of 12.9% from 2024 to 2031.The Oral category is the fastest growing segment of the Pediatrics Medicine industry  Market Dynamics of Pediatrics Medicine MarketKey Drivers for Pediatrics Medicine MarketIncreasing the investment in healthcare infrastructure to Boost Market GrowthThe increasing healthcare expenditure is a significant factor that influences the growth rate of the pediatric drugs market, as it contributes to the improvement of its infrastructure. Additionally, it is the objective of numerous government organizations to enhance the healthcare infrastructure by increasing funding, which will have a further impact on the market dynamics. In addition, the pediatric drug market will be expanded by the increasing prevalence of obesity among children and the increasing number of initiatives by public and private organizations to raise awareness. In addition, the rising population and the evolving lifestyles of individuals will lead to the expansion of the pediatric drug market.Increasing the development of pediatric medicine formulationsIn the past two decades, regulators have made significant efforts to motivate pharmaceutical companies to develop pediatric medicines, particularly orphan medications for rare and ultra-rare diseases and drugs for cystic fibrosis. The number of new routes of administration options for patients in this category has increased significantly in recent years as a result of new regulations and legislation. Although the design, recruitment, and execution of a variety of pediatric clinical trials, as well as the determination of acceptable end points, remain challenging endeavors, numerous significant clinical research organizations now offer specialized services in this area. Moreover, the market is experiencing further growth as a result of the rise in FDA approvals for these medications. For instance, In May 2019, Jacobus Pharmaceutical Company announced that it had received U.S. FDA approval for RUZURGI tablets (amifampridine) under Priority Review and Fast Track designations. It was also granted orphan drug designation for the treatment of Lambert Eaton myathenic syndrome (LEMS) in the pediatric population.Restraint Factor for the Pediatrics Medicine MarketThe restricted market exclusivity, will Limit Market GrowthThe pediatric drug market's expansion is significantly impeded by the limited duration of market exclusivity. Compared to pharmaceuticals intended for adults, pediatric medications frequently possess patent protection and market exclusivity that are much brief. Pharmaceutical companies' financial incentives for investing in pediatric drug development are diminished by these constraints. Pharmaceutical enterprises are generally attracted to markets that can generate substantial profits and recoup their research and development investments. Nevertheless, the pediatric sector's smaller patient populations and shorter exclusivity periods frequently make it more difficult to substantiate the allocation of resources for research and development endeavors. This constraint can have a significant effect on the development of medicines for uncommon pediatric diseases, as the number of patients is exceedingly restricted.Impact of Covid-19 on the Pediatrics Medicine MarketA varied impact was...

根据认知市场研究，全球儿科医学市场规模预计在2024年将达到1315.42亿美元。从2024年至2031年，该市场规模将以13.20%的复合年增长率（CAGR）扩张。北美在全球收入中占据了超过40%的份额，2024年的市场规模为526.16亿美元，并将在2024年至2031年以11.4%的复合年增长率增长。欧洲在全球收入中占比超过30%，市场规模为394.63亿美元。亚太地区在全球收入中占比约为23%，2024年的市场规模为302.55亿美元，并将在2024年至2031年以15.2%的复合年增长率增长。拉丁美洲在全球收入中占比超过5%，2024年的市场规模为65.77亿美元，并将在2024年至2031年以12.6%的复合年增长率增长。中东和非洲在全球收入中占比约为2%，2024年的市场规模估计为26.31亿美元，并将在2024年至2031年以12.9%的复合年增长率增长。口腔类别是儿科医学行业增长最快的部分。
儿科医学市场动态
儿科医学市场的主要驱动因素
增加医疗基础设施投资以促进市场增长
医疗保健支出的增加是影响儿科药物市场增长速度的重要因素，因为它有助于其基础设施的改善。此外，众多政府组织的目标是通过增加资金来提升医疗保健基础设施，这将对市场动态产生进一步的影响。此外，儿科药物市场将通过儿童肥胖问题的日益严重以及公共和私营组织提高公众意识的举措而得到扩张。此外，人口的增长和个体生活方式的演变也将导致儿科药物市场的扩张。
增加儿科药物制剂的开发
在过去二十年里，监管机构做出了重大努力，以激励制药公司开发儿科药物，特别是针对罕见和超罕见疾病以及囊性纤维化药物的孤儿药物。近年来，由于新的法规和立法，该类别患者的新给药途径选项数量显著增加。尽管设计、招募和执行各种儿科临床试验，以及确定可接受的终点仍然是具有挑战性的工作，但许多重要的临床研究组织现在提供该领域的专业服务。此外，这些药物的市场批准率的提高也促进了市场的进一步增长。例如，2019年5月，雅各布斯制药公司宣布，其RUZURGI片剂（氨酚苯海拉明）已获得美国FDA的优先审评和快速通道指定批准，并获得了针对儿科人群治疗Lambert-Eaton肌无力综合征（LEMS）的孤儿药指定。
儿科医学市场的制约因素
受限的市场独家性将限制市场增长
与针对成人的药物相比，儿科药物通常拥有较短的专利保护和市场独家性。这些限制削弱了制药公司在儿科药物开发上的财务激励。制药企业通常被能够产生巨额利润并收回研发投资的市场的吸引力所吸引。然而，儿科部门的较小患者群体和较短的独家期往往使得证明为研发活动分配资源更加困难。这种限制对罕见儿科疾病药物的开发具有重大影响，因为患者数量极其有限。
新冠疫情对儿科医学市场的影响
新冠疫情对儿科医学市场产生了多样化的影响...